Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$93 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$-7 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6
Industry P/E
--
EV/EBITDA
-3.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
27,419,200
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Miromatrix Medical Inc (MIRO)
| 13.4 | 1.2 | 147.4 | 19.4 | -- | -- | -- |
|
BSE Sensex*
| -13.7 | -10.1 | -14.2 | -3.8 | 7.4 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Miromatrix Medical Inc (MIRO)
| 13.4 | -36.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Miromatrix Medical Inc (MIRO)
|
3.4 | 93.0 | 1.0 | -27.1 | -2,935.3 | -125.1 | -- | 6.0 |
| 0.7 | 16.2 | 0.4 | -60.9 | -3,716.2 | -- | -- | 17.3 | |
| 3.5 | 8.2 | 0.0 | -39.4 | -- | -54.6 | -- | 0.4 | |
| 228.7 | 43,154.8 | 2,300.4 | -750.2 | -35.0 | -28.5 | -- | 16.9 |
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization... designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota. Read more
CEO & Director
Dr. Jeffrey James Ross Ph.D.
CEO & Director
Dr. Jeffrey James Ross Ph.D.
Headquarters
Eden Prairie, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Miromatrix Medical Inc (MIRO) is $3.39 (NASDAQ) as of 22-Dec-2023 09:30 EDT. Miromatrix Medical Inc (MIRO) has given a return of 19.37% in the last 1 years.
Since, TTM earnings of Miromatrix Medical Inc (MIRO) is negative, P/E ratio is not available.
The P/B ratio of Miromatrix Medical Inc (MIRO) is 5.98 times as on 22-Dec-2023, a 52 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-2.09
|
2.41
|
|
2021
|
-3.45
|
0.95
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-2.09
|
2.41
|
The 52-week high and low of Miromatrix Medical Inc (MIRO) are Rs -- and Rs -- as of 02-Apr-2026.
Miromatrix Medical Inc (MIRO) has a market capitalisation of $ 93 Mln as on 22-Dec-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Miromatrix Medical Inc (MIRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.